Li B.,Zhejiang University |
Zhu X.,Taizhou Cancer Hospital |
Sun L.,Zhejiang University |
Yuan L.,Fudan University |
And 3 more authors.
Oncotarget | Year: 2014
Conventional non-surgical therapeutic regimens against osteosarcoma are subject to chemoresistance and tumor relapse, and immunotherapy may be promising for this tumor. However, it's hard to find satisfactory epitopes for immunotherapy against osteosarcoma. Cancer/testis antigens (CTAs), such as MAGE-A family and NY-ESO-1, the potential antigens that almost exclusively express in tumor cells and immune-privileged sites, have been found expressed in osteosarcoma also. Nevertheless, the expression of CTAs is downregulated in many tumors, constraining the application of immunotherapy. In this article, we demonstrate that the expression of MAGE-A family and NY-ESO-1 in osteosarcoma cells can be upregulated following treatment with demethylating agent 5-aza-2'-deoxycytidine and consequently induces a CTA specific CD8+ T-cell response against osteosarcoma in vitro and in vivo. The in vivo imaging was realized by using luciferase-transfected HOS cells and DiR labeled T-cells in severely combined immunodeficiency mouse models. Cytotoxic T cells specifically recognizing MAGE-A family and NY-ESO-1 clustered at the tumor site in mice pre-treated with DAC and resulted in tumor growth suppression, while it was not observed in mice without DAC pre-treatment. This study is important for more targeted therapeutic approaches and suggests that adoptive immunotherapy, combined with demethylating treatment, has the potential for non-surgical therapeutic strategy against osteosarcoma.
Ye L.,Taizhou Cancer Hospital |
Song Q.,Taizhou Cancer Hospital
International Journal of Clinical and Experimental Medicine | Year: 2015
We investigated the effect of synthesized retinoic acid-poly(ethylene glycol)-thiol gold nanoparticle conjugates on cervical carcinoma cells. Cervical cancer is the major cause of deaths for the women of reproductive age in the developing countries. Compared to retinoic acid, the nanoparticle conjugates exhibited better activity against cervical carcinoma. Selective delivery of gold nanoparticle conjugates to estrogen receptor positive cervical cancer cells with 6-fold enhanced drug potency was observed. Transfer of gold nanoparticles was found to be dominated by estrogen ligand and receptor. It appeared that retinoic acid nanoparticle conjugates were selectively taken and retained by the estrogen receptor alpha present in the plasma membrane. Thus IC50 values for RA-PEG-SH were significantly improvedon nanoparticle ligation. Cells on treatment with RA-PEG-SH-AuNPsshowed growth inhibition at 12 and 24 h after incubation. The IC50 for RA in RA-PEG-SH-AuNPs after 12 and 24 h were 3 and 1 μM, respectively. Thus, the use of RA nanoparticle conjugates can be a better strategy for cervical carcinoma treatment. © 2015 E-Century Publishing Corporation. All rights reserved.
Ye L.,Taizhou Cancer Hospital |
Song Q.,Taizhou Cancer Hospital
Tropical Journal of Pharmaceutical Research | Year: 2015
Purpose: To investigate the effect of withaferin A on the suppression of the anti-apoptotic genes, BCL2, Bcl-xL, XIAP and Survivin), in cervical carcinoma cells. Methods: Annexin V-FITC/propidium iodide (PI) staining was used for the investigation of cell apoptosis. RNA RNeasy Kits was used to isolate RNA and Omniscript RT to reverse and transcribe the mRNA. Quantitative real-time polymerase chain reaction (qPCR) was performed using Taq PCR Master Mix Kit. Results: Withaferin A (WFA) treatment reduced mRNA and protein levels of antiapoptotic genes in MCF-7 and HeLa cervical carcinoma cells. Suppression of BCL2, Bcl-xL, XIAP and Survivin induced a significant anti-proliferative effect. Treatment with WFA at a concentration of 20 μM, decreased cell viability and induced apoptosis. In MCF-7 cells, knockdown of BCL2, Bcl-xL, XIAP and Survivin caused 4-fold enhancement in apoptosis rate and 53% decrease in cell viability. Conclusion: WFA significantly leads to knockdown of antiapoptotic genes and is, therefore, a promising treatment strategy for cervical cancer. © Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria. All rights reserved.
Ba L.,Zhengzhou University |
Tan H.,Zhengzhou University |
Xiao H.,Zhengzhou University |
Guan Y.,Taizhou Cancer Hospital |
And 2 more authors.
Acta Radiologica | Year: 2015
Background: Primitive neuroectodermal tumors (PNETs) constitute a rare type of malignant neuroectodermal tumors that have chromosomal translocations identical to Ewing's sarcoma (ES), and the characteristics of this disease remain unclear. Purpose: To describe the clinical, radiological, and pathological features of peripheral PNETs (pPNETs) to enhance their recognition. Material and Methods: The clinical, imaging, and pathologic findings of 35 patients with pPNETs were retrospectively reviewed, all being confirmed by biopsy or surgical pathology. All 35 patients had preoperative computed tomography (CT) examinations; 10 patients had preoperative magnetic resonance imaging (MRI) studies. Results: Of 35 pPNET patients, 54.3% had a primary tumor in soft tissue, the others in bone. On plain CT images, 33 lesions demonstrated heterogeneous hypodense masses with multiple lamellar lower density, and with osteolytic destruction if the tumor originated in bone. Calcification was only found in five lesions arising in soft tissue. All lesions enhanced heterogeneously with varying areas of cystic changes, and all lesions in bone and 52.6% of lesions in soft tissue showed ill-defined margins after contrast administration. On MRI, these tumors appeared in conjunction with osteolytic bone destruction and irregular soft tissue masses iso-to hypointense to skeletal muscle on T1-weighted images and showed heterogeneously high intensity on T2-weighted images. All lesions enhanced heterogeneously with cystic changes. Homer-Wright rosettes were observed in 15 lesions, and 97.1% lesions were positive for CD99 in histopathological results. Conclusion: pPNETs can involve any part of the body, and a large, ill-defined, aggressive soft tissue mass and heterogeneous enhancement with or without osteolytic bone destruction on CT or MR images could suggest the diagnosis. © The Foundation Acta Radiologica 2014.
Zhu X.-B.,Taizhou Cancer Hospital |
Ye Z.-M.,Zhejiang University |
Tao Z.-G.,Taizhou Cancer Hospital
Journal of Practical Oncology | Year: 2015
Objective: To evaluate the clinical effects of zoledronic acid in combination with radiotherapy in the treatment of bone metastases. Methods: One-hundred-twenty patients with bone metastases were enrolled in this study. Patients were randomly assigned to three groups: 40 cases were treated with radiotherapy at a plan of 30 Gy/10 f/2 w (group A), 40 cases were treated with 4 mg zoledronic acid intravenously (group B) and 40 cases were treated with zolendronic acid in combination with radiotherapy (group C). Pain was evaluated with verbal rating scale (VRS), general performance was evaluated with KPS scores and bone reparation rate was documented before and after treatment in 3 groups. Results: All groups were benefited after treatment in VRS and KPS scores. The response rates of group A, B and C were 75.0% (30/40), 72.5% (29/40), 97.5% (39/40), respectively (P<0.05). The improvement rates of quality of life were 75.0%, 70.0% and 92.5%, respectively (P<0.05). The bone reparation rates were 35.0%, 37.5% and 60.0%, respectively (P<0.05). Conclusion: Zoledronic acid in combination with radiotherapy showed promising results, and this therapeutic regimen may be a better choice in the treatment of bone metastases. ©, 2015, Journal of Practical Oncology, Editorial Board. All right reserved.